Is it expected to replace current breast cancer screening methods and diagnostic tools?
No, the probe is intended to provide additional information after initial screening has taken place. • How does the software work? The software enables the physician to detect not just the absolute values of the six cancer indicators in a suspicious breast lesion, but the values relative to normal tissue in specific patients. As the probe passes through a patient’s normal tissue, the physician signals the computer to record these measurements as “not cancer.” Then he or she proceeds to the suspicious region and makes the same measurements, comparing the results with those previously obtained from normal tissue. • How soon will it be on the market? We estimate it will take 18 months to design and fabricate the first commercial prototype and complete the first clinical study. The regulatory approval process could take another year. Our current estimates indicate that the BioLuminate Smart ProbeTM will be commercially available by the end of 2005. • How will it save healthcare dollars? Br
Related Questions
- What is the difference between the Cochrane Diagnostic Test Accuracy Working Group (DTAWG) and the Screening and Diagnostic Test Methods Group (SDTMG)?
- Do non-specific minimal signs in a biennial mammographic breast cancer screening programme need further diagnostic assessment?
- Is it expected to replace current breast cancer screening methods and diagnostic tools?
